Authors' recommendations: Description of Technology: This report focuses on the use of Imlygic (talimogene laherparepvec, also known as OncovexGM-CSF and T-VEC [henceforth referred to as talimogene]; Amgen Inc.) for the treatment of malignant melanoma. Talimogene is the first oncolytic virus therapeutic agent to receive Food and Drug Administration marketing approval. Oncolytic viruses are nonpathogenic, genetically modified viral strains that selectively infect and kill neoplastic cells. Talimogene is a genetically modified live oncolytic herpes simplex virus that expresses granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF improves the systemic antitumor effects of talimogene and is widely used as a vaccine adjuvant. Talimogene is injected directly into cutaneous, subcutaneous, or nodal lesions that are visible, palpable, or can be accessed by ultrasound guidance. The injection volume is based upon the lesion size, and multiple lesions may be treated at each session provided that the total volume does not exceed 4.0 milliliters. Patient Population: Talimogene is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=38986

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: <p>HAYES, Inc.</p>